Get the Stockscreener App
4.32
2.48%
-0.11
After Hours:
4.32
Pluri Inc stock is traded at $4.32, with a volume of 5,255.
It is down -2.48% in the last 24 hours and down -5.16% over the past month.
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.
See More
Previous Close:
$4.43
Open:
$4.295
24h Volume:
5,255
Relative Volume:
0.22
Market Cap:
$24.01M
Revenue:
$598.00K
Net Income/Loss:
$-21.81M
P/E Ratio:
-1.0485
EPS:
-4.12
Net Cash Flow:
$-16.66M
1W Performance:
+1.89%
1M Performance:
-5.16%
6M Performance:
-24.61%
1Y Performance:
+3.75%
1-Day Range:
$4.2001
$4.39
1-Week Range:
$4.15
$4.50
52-Week Range:
$4.07
$8.48
Pluri Inc Stock (PLUR) Company Profile
Name
Pluri Inc
Sector
Industry
Phone
972-74-710-7171
Address
MATAM ADVANCED TECHNOLOGY PARK, HAIFA
Compare PLUR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLUR
Pluri Inc
|
4.32 | 24.01M | 598.00K | -21.81M | -16.66M | -4.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pluri Inc Stock (PLUR) Latest News
Comparing Adverum Biotechnologies (NASDAQ:ADVM) & Pluri (NASDAQ:PLUR) - Defense World
Anavex Life Sciences (NASDAQ:AVXL) vs. Pluri (NASDAQ:PLUR) Critical Comparison - Defense World
BCLI: Plans Coming Together for Phase 3b Trial of NurOwn® in ALS… - MSN
Pluristyx Announces Immediate Availability of GMP-Compliant PSXi013 iPSC Line for Advanced Therapy Development - Business Wire
Head to Head Review: Pluri (NASDAQ:PLUR) & Gilead Sciences (NASDAQ:GILD) - Defense World
Pluristem stock touches 52-week low at $4.11 amid market challenges - Investing.com India
Pluristem stock touches 52-week low at $4.11 amid market challenges By Investing.com - Investing.com South Africa
BrainStorm secures FDA protocol for ALS trial By Investing.com - Investing.com Canada
Financial Contrast: Evaxion Biotech A/S (NASDAQ:EVAX) & Pluri (NASDAQ:PLUR) - Defense World
BrainStorm Issues 2024 Letter to Shareholders - The Malaysian Reserve
BrainStorm secures FDA protocol for ALS trial - Investing.com India
BrainStorm Issues 2024 Letter to Shareholders – Company Announcement - Financial Times
Pluri (NASDAQ:PLUR) Trading Down 2.8% – Here’s Why - Defense World
Pluri Congratulates Mesoblast on FDA Approval of Cell Therapy for Graft-Versus-Host Disease - Content Media Solution
Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease - The Manila Times
Pluri (PLUR) Celebrates FDA Milestone: First MSC Cell Therapy Approval Validates Regenerative Medicine Future - StockTitan
Adipose-derived Stem Cell Market Key Players Analysis - openPR
When the Price of (PLUR) Talks, People Listen - Stock Traders Daily
Pluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025 - The Manila Times
Pluri's PluriCDMO Nominated for CDMO of the Year Award, Showcasing Revolutionary Cell Therapy Manufacturing - StockTitan
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing - Yahoo Finance
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing - Marketscreener.com
(PLUR) Technical Data - Stock Traders Daily
Pluri Inc (PLUR): Worth A Small Bite At $5.57 - Stocks Register
Pluri Inc. faces Nasdaq delisting over equity shortfall - Investing.com
Pluri Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear Threat Concerns - The Manila Times
Pluri Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear - EIN News
How Cultivated Meat Carved Out Its Plate in History - SynBioBeta
Pluri First Quarter 2025 Earnings: US$1.08 loss per share (vs US$0.96 loss in 1Q 2024) - Yahoo Finance
BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - StreetInsider.com
BrainStorm Cell Reports $2.7M Loss, Plans Phase 3b ALS Trial Despite Low Cash | BCLI Stock News - StockTitan
Pluri: Fiscal Q1 Earnings Snapshot - San Francisco Chronicle
Pluri (PLUR) to Present at Q4 Virtual Investor Summit: Biotech Showcase for Growth | PLUR Stock News - StockTitan
Pluri (PLUR) Announces Key Collaboration, Driving Stock Upward - Stocks Telegraph
BrainStorm Teams with Pluri for Key NurOwn ALS Trial Manufacturing Partnership | PLUR Stock News - StockTitan
BrainStorm Teams with Pluri for Key NurOwn ALS Trial Manufacturing Partnership - StockTitan
Pluri And Bar-Ilan University Partner To Advance MAIT Cell Therapy For Solid Tumors - Contract Pharma
Pluri Flat on Funding From Innovation Authority - Baystreet.ca
Pluri Collaborates with Bar-Ilan University to Advance - GlobeNewswire
Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority - StockTitan
Cell And Gene Therapy Contract Development And Manufacturing - openPR
Renaissance Technologies LLC Decreases Position in Pluri Inc. (NASDAQ:PLUR) - Defense World
(PLUR) Technical Pivots with Risk Controls - Stock Traders Daily
Plurilock (PLUR.V) lands $19 million deal, largest in their history - Equity.Guru
Pluri Inc. regains compliance with Nasdaq listing rules - Investing.com India
Pluri Inc. regains compliance with Nasdaq listing rules By Investing.com - Investing.com UK
Pluri Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com
TomTom (OTCMKTS:TMOAF) Short Interest Down 34.8% in September - Defense World
(PLUR) Proactive Strategies - Stock Traders Daily
The Plurilock (PLUR.V) rip is over: But is that the end of the play? - Equity.Guru
Plurilock’s Behavioral Biometrics: Next-Gen Cybersecurity with Scott Meyers - The Deep Dive
Pluri Inc Stock (PLUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):